Reflecting our growing global reach and expanded

scope, an updated mission statement and new tagline

With World Hepatitis Day coming on July 28, the Hepatitis B Foundation is introducing an updated mission statement and new tagline intended to better reflect the expanded work being done by the organization’s staff in liver disease broadly, not only hepatitis B, with a global reach.

Paired with the organization’s logo, the new tagline is, “A World Free of Hepatitis B, Hepatitis D and Liver Cancer.”

The new mission statement is one sentence: “The Hepatitis B Foundation is a nonprofit organization working around the world to improve the lives of those affected by hepatitis B, hepatitis D and liver cancer; drive prevention, diagnosis and treatment and accelerate scientific research to achieve cures.” Please read more here.

Special edition: Real conversations about the hep B vaccine

To commemorate World Hepatitis Day, the Hepatitis B Foundation has launched a new video series—Protection from Day One: Real Conversations about the Hepatitis B Vaccine. This three-part series aims to combat stigma, dispel misconceptions and elevate the voices of families and advocates navigating chronic hepatitis B. By sharing real, unfiltered experiences, the Foundation underscores the life-saving importance of the hepatitis B birth dose and timely vaccination.

World Hepatitis Day 2026: #justB storytellers spread awarness

As we approach World Hepatitis Day 2026, we are excited to share the Hepatitis B Foundation’s new #justB Storyteller Campaign.


This year, our incredible #justB storytellers from across the globe are raising their voices to share a deeply personal and vital message: What hepatitis B elimination truly means to them. From Florida to Nigeria, Japan to Moldova, these stories represent the diverse, lived experiences of individuals who aim to inspire action toward elimination

Share your story: Join the Foundation's new storytelling project

Your story has the power to change the world.


The Hepatitis B Foundation is looking for new storytellers to participate in our upcoming storytelling project workshop. This workshop is designed to bring together individuals living with or affected by hepatitis B to learn how to effectively share their personal journeys. Learn how to: Educate the public, raise awareness and inspire policy change.


To learn about this project and submit your application, visit our website here.

Partnering to reduce liver cancer disparities at PC3

The Hepatitis B Foundation recently joined health care providers, researchers and community organizations at the 2026 Philadelphia Communities Conquering Cancer (PC3) Conference to address cancer disparities across Philadelphia.


We are proud that our community partner, the African Family Health Organization (AFAHO), presented on improving liver cancer awareness and hepatitis B screening within Philadelphia's African and Caribbean communities. We continue to support AFAHO through our capacity building and Hep B United Philadelphia program.

L-R: Chari Cohen, DrPH, MPH; Stella Dlamini, MPH; Noah Trudeau, MSPH

Follow us on TikTok: @hepbfoundation

The Hepatitis B Foundation is officially on TikTok! We are taking our mission to a whole new platform to share health education, dispel common hepatitis B myths, highlight powerful patient stories and give you a behind-the-scenes look at our advocacy work.


Whether you're looking for quick public health facts or want to help us spread awareness to a younger global audience, we’d love to have your support.


👉 Follow @hepbfoundation on TikTok and join the conversation today!

Help us improve hepatitis B care & treatment access in Africa

The African Hepatitis B Advocacy Coalition (ABAC), a program of the Hepatitis B Foundation, is launching a crucial survey to better understand the current landscape of hepatitis B care, challenges in accessing treatment, and areas where we can make a real difference. This will inform global and national strategies to improve equitable access to treatment.

The survey is available in English and French.

Share your voice on the Foundation's quality-of-life survey

The Hepatitis B Foundation is seeking participants for a new research study titled HepB PROACTive (Hepatitis B: Patient-Reported Outcomes, Adherence and Quality-of-Life Tracking).


The goal of this program is to better understand the daily experiences, treatment challenges and overall well-being of individuals living with chronic hepatitis B.

We're seeking adults age 18+ with hepatitis B living anywhere in the world.

Participants may also complete the survey in

Traditional Chinese (繁體中) or Simplified Chinese (简体中文).

New blog: New hepatitis delta drug, Hepcludex, now approved in the U.S.

Please read the full blog here.

We are sharing a historic milestone in the fight against viral hepatitis: Hepcludex (bulevirtide) has officially received FDA approval, making it the first and only approved treatment for chronic hepatitis delta in the U.S.


Now it's time to expand testing! With an effective treatment finally available, identifying infections early is more important than ever. If you're living with hepatitis B, please speak to a health care provider about getting tested for hepatitis delta.

B Heppy Podcast: The cost of navigating hepatitis B treatment in America

For many living with chronic hepatitis B in the U.S., finding the right medical care is only half the battle—the next hurdle is being able to afford it. In the latest episode of the B Heppy podcast, hosts Bright and Anousha sit down with Carl Schmid, executive director of the HIV+Hepatitis Policy Institute, for a critical and timely conversation on the financial realities of managing hepatitis B. Listen to the podcast here.

Clinical Education Program: HBV in key communities

Check out this free CME program, HBV in Key Communities: Strategies to Overcome Barriers and Elevate Care.


Clinicians will gain confidence in hepatitis B screening and management, and learn how to identify and overcome cultural and logistical barriers that hinder engagement with HBV care in key populations, such as Asian-Americans, African immigrants and U.S. veterans.

New training module: Funding the fight against hepatitis

Obtaining resources is one of the biggest hurdles in the global effort to eliminate viral hepatitis.


To help you meet this challenge, the Hepatitis B Foundation has launched a new, free online course: Funding the Fight Against Hepatitis, intended for advocates, health care professionals or staff with community organizations.

Upcoming Events

July 28

World Hepatitis Day, [media toolkit]

Aug. 26

3 p.m. EDT | 1 p.m. MT | 9 a.m. HT

Register here

Webinar: Understanding the HepB Birth Doses' impact on series completion amid declining infant HepB Vaccination rates

Sept. 6

1 - 2:30 p.m. SGT

Community Forum at the 2026

International HBV Meeting, Singapore

Sept. 6-10

International HBV Meeting, Singapore

Journal article of the month

Long-term protection following a primary series of

hepatitis B vaccine in Alaska Native children and adults


Hepatology Communications

June 19, 2026

10(7):e0978. doi: 10.1097/HC9.0000000000000978


Steinberg J, Blake I, Stevenson T, Wheelock H, Bruden D, Townshend-Bulson L, Klejka J, Peterson M, Cartwright E, Drobeniuc J, Scobie H, Bruce M, Fischer M, McMahon B


This article, co-authored by Brian McMahon, MD, an advisor to the Hepatitis B Foundation, reports on research to determine the duration of protection provided by the hepatitis B vaccine and the need for booster doses. The team examined a group of 1351 persons who completed the hepatitis B vaccine primary series in 1981-1982. "The overall proportion with serologic evidence of protection was... 91% at 41 years after vaccination." Over the 41 period studied, 16 persons had evidence of a breakthrough infection; none developed chronic hepatitis B. The authors concluded, "Our findings support the recommendation that booster doses are not needed in endemic areas."

The Hepatitis B Foundation is a nonprofit organization working around the world to improve the lives of those affected by hepatitis B, hepatitis D and liver cancer; drive prevention, diagnosis and treatment and accelerate scientific research to achieve cures.

Learn more about our research and education programs at www.hepb.org

Facebook  Twitter  Instagram  Youtube